Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site.

# Vit-Buckle Society

## Sitemaps

- [XML Sitemap](https://vitbucklesociety.org/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [VBS Journal Club](https://vitbucklesociety.org/blog/) - Read about member updates and vitreoretinal surgery news on the Vit-Buckle Society blog.
- [Paracentral Acute Middle Maculopathy and Risk of Cardiovascular Disease, Stroke, and Death: A Longitudinal Study](https://vitbucklesociety.org/2026/07/11/paracentral-acute-middle-maculopathy-and-risk-of-cardiovascular-disease-stroke-and-death-a-longitudinal-study/) - July 2026 Danny A. Mammo MD Cole Eye Institute Cleveland Clinic Cleveland, OH Limoli C, Raja LD, Wagner SK, et al. Paracentral Acute Middle Maculopathy and Risk of Cardiovascular Disease, Stroke, and Death: A Longitudinal Study. American Journal of Ophthalmology. 2024;267:286-292. Paracentral acute middle maculopathy (PAMM) describes a hyperreflective band observed
- [Accelerometer-Measured Physical Activity and the Risk of Diabetic Retinopathy](https://vitbucklesociety.org/2026/06/07/accelerometer-measured-physical-activity-and-the-risk-of-diabetic-retinopathy/) - June 2026 Danny A. Mammo MD Cole Eye Institute, Cleveland Clinic Cleveland, OH Levenson JN, Dias CG, Shah J, Kovacs KD. Association of Accelerometer-Measured Physical Activity With Presence of Diabetic Retinopathy. Journal of VitreoRetinal Diseases. 2026;10(3):482-485. Diabetes and its microvascular complications impose significant social and economic burdens worldwide, highlighting an urgent need for
- [Oral acetylcysteine and the risk of age-related macular degeneration](https://vitbucklesociety.org/2026/05/16/oral-acetylcysteine-and-the-risk-of-age-related-macular-degeneration/) - May 2026 Danny A. Mammo MD Cole Eye Institute, Cleveland Clinic Cleveland, OH Tsai HR, Chang WC, Lee YC. Oral acetylcysteine and the risk of age-related macular degeneration. Ophthalmology. 2026;133(2):223-232. This retrospective cohort study from Taiwan investigated whether oral N-acetylcysteine (NAC) - an antioxidant and glutathione precursor - is associated with a reduced risk
- [Comparison of Neovascular Age-Related Macular Degeneration Outcomes in Established vs New Patients of a Retina Practice](https://vitbucklesociety.org/2026/04/04/comparison-of-neovascular-age-related-macular-degeneration-outcomes-in-established-vs-new-patients-of-a-retina-practice/) - April 2026 Danny A. Mammo MD Cole Eye Institute, Cleveland Clinic Cleveland, OH Du J, Chen MY, Dasan R, et al. Comparison of Neovascular Age-Related Macular Degeneration Outcomes in Established vs New Patients of a Retina Practice. Journal of VitreoRetinal Diseases. 2026;10(1):11-19. doi:10.1177/24741264251374576 Age-related macular degeneration (AMD) is a leading cause of blindness in the
- [Rates of endophthalmitis in prefilled versus nonprefilled syringes for intravitreal injections](https://vitbucklesociety.org/2026/03/15/rates-of-endophthalmitis-in-prefilled-versus-nonprefilled-syringes-for-intravitreal-injections/) - March 2026 Danny A. Mammo MD Cole Eye Institute, Cleveland Clinic Cleveland, OH Zhang C, Lai DA, AbouKasm G, et al. Rates of endophthalmitis in prefilled versus nonprefilled syringes for intravitreal injections. Ophthalmology Retina. 2026;10(2):165-175. Intravitreal injections (IVIs) are the most common therapeutic procedure in ophthalmology, with over a million administered annually in the United
- [Macular Hole Closure by Internal Limiting Membrane Flap without Gas Tamponade versus Conventional Surgery](https://vitbucklesociety.org/2025/11/05/macular-hole-closure-by-internal-limiting-membrane-flap-without-gas-tamponade-versus-conventional-surgery/) - November 2025 Danny A. Mammo MD Cole Eye Institute, Cleveland Clinic Cleveland, OH Szeto SKH, Lam JTW, Yu AHY, et al. Ophthalmology Retina. Online ahead of print June 13, 2025. doi:10.1016/j.oret.2025.06.005 Macular hole (MH) repair has long leaned on intraoperative gas tamponade and strict postoperative positioning to support closure and healing. This study challenges that
- [Short-term Reactivation of Retinopathy of Prematurity after Primary Ranibizumab Treatment](https://vitbucklesociety.org/2024/10/29/short-term-reactivation-of-retinopathy-of-prematurity-after-primary-ranibizumab-treatment/) - November 2024 Monique Munro MD FRCSC University of Calgary, Section of Ophthalmology Calgary Alberta Strawbridge J, Cheng JY, Gundlach BS, Gillespie T, Karmouta R, Khitri M, Chu A, Tsui I. Short-term reactivation of retinopathy of prematurity after primary ranibizumab treatment. Retina. 2024 Nov 1;44(11):1945-1951. Current treatment options for Type 1 retinopathy of prematurity (ROP) includes
- [Clinical Outcomes of Faricimab in Patients with Previously Treated Neovascular Age-Related Macular Degeneration](https://vitbucklesociety.org/2024/04/02/1707/) - May 2024 Joshua Uhr MD Retinal & Ophthalmic Consultants Northfield, NJ Pandit SA, Momenaei B, Wakabayashi T, Mansour HA, Vemula S, Durrani AF, Pashaee B, Kazan AS, Ho AC, Klufas M, Regillo C, Yonekawa Y, Hsu J, Kuriyan A, Chiang A. Clinical Outcomes of Faricimab in Patients with Previously Treated Neovascular Age-Related Macular Degeneration.
- [Oral Hypoxia-Inducible Factor 2a inhibitor Belzutifan in Ocular von Hippel-Lindau Disease](https://vitbucklesociety.org/2024/08/25/oral-hypoxia-inducible-factor-2a-inhibitor-belzutifan-in-ocular-von-hippel-lindau-disease/) - August 2024 Kapil Mishra M.D. Gavin Herbert Eye Institute University of California, Irvine Wiley HE, Srinivasan R, Maranchie JK, et al. Oral hypoxia-inducible factor 2α inhibitor belzutifan in ocular von hippel-lindau disease. Ophthalmology. Published online June 2024:S0161642024003191. Von Hippel-Lindau (VHL) disease is a hereditary condition characterized by the development of tumors in multiple organs
- [Recovery of Vision in Open Globe Injury Patients with Initial No Light Perception Vision](https://vitbucklesociety.org/2024/08/25/recovery-of-vision-in-open-globe-injury-patients-with-initial-no-light-perception-vision/) - September 2024 Hasenin Al-khersan M.D. Retina Consultants of Texas Houston, TX Sherif NA, Hoyek S, Wai K, Makhoul KG, Bitar R, Tieger M, Lorch AC, Patel NA, Armstrong GW. Recovery of Vision in Open Globe Injury Patients with Initial No Light Perception Vision. Ophthalmol Retina. 2024 Jul;8(7):617-623. Open-globe injuries (OGI) consist of full thickness
- [Endophthalmitis after Anti-VEGF Intravitreal Injections with Aqueous Chlorhexidine versus Povidone-Iodine as Ocular Antiseptics](https://vitbucklesociety.org/2024/03/19/endophthalmitis-after-anti-vegf-intravitreal-injections-with-aqueous-chlorhexidine-versus-povidone-iodine-as-ocular-antiseptics/) - May 2024 Samir N. Patel, MD Retina Vitreous Consultants, Pittsburgh PA Ton NS, Goncharov V, Zapata I, Adam MK. Endophthalmitis after Anti-VEGF Intravitreal Injections with Aqueous Chlorhexidine versus Povidone-Iodine as Ocular Antiseptics. Ophthalmol Retina. 2023 Dec 18:S2468-6530(23)00648-6. PMID: 38122867. Infectious endophthalmitis is a rare but potentially severe complication of intravitreal injections. Multiple strategies have
- [Intravitreal Therapy for Uveitic Macular Edema - Ranibizumab versus Methotrexate versus the Dexamethasone Implant: The MERIT Trial Results](https://vitbucklesociety.org/2024/01/09/intravitreal-therapy-for-uveitic-macular-edema-ranibizumab-versus-methotrexate-versus-the-dexamethasone-implant-the-merit-trial-results/) - February 2024 Jordan D. Deaner, MD Uveitis and Vitreoretinal Surgery Mid Atlantic Retina, Wills Eye Hospital Assistant Professor, Thomas Jefferson University Philadelphia, PA Multicenter Uveitis Steroid Treatment Trial (MUST) Research Group, Writing Committee:; Acharya NR, Vitale AT, Sugar EA, Holbrook JT, Burke AE, Thorne JE, Altaweel MM, Kempen JH, Jabs DA. Intravitreal Therapy for
- [Retinal Displacement after Scleral Buckle versus Combined Buckle and Vitrectomy for Rhegmatogenous Retinal Detachment](https://vitbucklesociety.org/2023/12/05/retinal-displacement-after-scleral-buckle-versus-combined-buckle-and-vitrectomy-for-rhegmatogenous-retinal-detachment/) - January 2024 Shivani V. Reddy, MD Talley Eye Institute Evansville IN Bansal A, Naidu SC, Marafon SB, et al. Retinal Displacement after Scleral Buckle versus Combined Buckle and Vitrectomy for Rhegmatogenous Retinal Detachment: ALIGN Scleral Buckle versus Pars Plana Vitrectomy with Scleral Buckle. Ophthalmol Retina. 2023;7(9):788-793. doi:10.1016/j.oret.2023.05.012 Low integrity retinal attachment (LIRA), a
- [Risk of Endophthalmitis Based on Cumulative Number of Anti-Vascular Endothelial Growth Factor Intravitreal Injections](https://vitbucklesociety.org/2024/02/27/risk-of-endophthalmitis-based-on-cumulative-number-of-anti-vascular-endothelial-growth-factor-intravitreal-injections/) - February 2024 Matt R. Starr, MD Vitreoretinal Surgery Mayo Clinic Rochester, MN Rachel N. Israilevich, MD, Hana Mansour, MD, Samir N. Patel, MD, Sunir J. Garg, MD FACS, Michael A. Klufas, MD, Yoshihiro Yonekawa, MD, Carl D. Regillo, MD FACS, Jason Hsu, MD. Risk of Endophthalmitis Based on Cumulative Number of Anti-Vascular Endothelial Growth
- [Unexplained Vision Loss Associated With Intraocular Silicone Oil Tamponade in Rhegmatogenous Retinal Detachment Repair](https://vitbucklesociety.org/2023/11/19/unexplained-vision-loss-associated-with-intraocular-silicone-oil-tamponade-in-rhegmatogenous-retinal-detachment-repair/) - November 2023 Sushant Wagley MD Iowa Retina Consultants Des Moines, IA Pakravan P, Shaheen A, Patel V, Villalba MF, Dib B, Lai J, Rohowetz L, Chau V, Patel NA, Tzu JH, Wang AL, Alhoyek S, Scott N, Samara WA, Goduni L, Jung JJ, Russell JF, Mantopoulos D, Hajrasouliha AR, Savoie BT, Haddock LJ, Berrocal AM,
- [Retinal Detachment and Epiretinal Membrane Development in Fellow-eye Laser Prophylaxis](https://vitbucklesociety.org/2023/10/10/retinal-detachment-and-epiretinal-membrane-development-in-fellow-eye-laser-prophylaxis/) - October 2023 Danny A. Mammo MD Cole Eye Institute, Cleveland Clinic Cleveland, OH Wingelaar MJ, Smith BT. Retinal detachment and epiretinal membrane development in fellow-eye laser prophylaxis. Journal of VitreoRetinal Diseases. 2023;7(5):371-375. This study aimed to assess the safety and effectiveness of fellow-eye laser prophylaxis (FELP) in reducing the incidence of retinal detachment (RD) in
- [Post Hoc Analysis of FILLY Trial Using AI](https://vitbucklesociety.org/2023/06/18/post-hoc-analysis-of-filly-trial-using-ai/) - July 2023 Edward Korot, MD Retina Specialists of Michigan, Grand Rapids, MI Adjunct Clinical Assistant Professor, Stanford University, Palo Alto, CA Fu DJ, Glinton S, Lipkova V, et al. Deep-learning automated quantification of longitudinal OCT scans demonstrates reduced RPE loss rate, preservation of intact macular area and predictive value of isolated photoreceptor degeneration in
- [Effect of Duration of Macular Detachment on Visual Prognosis after Surgery for Macula-Off Retinal Detachment](https://vitbucklesociety.org/2023/06/04/effect-of-duration-of-macular-detachment-on-visual-prognosis-after-surgery-for-macula-off-retinal-detachment/) - June 2023 Mariam Mathai, MD Location/Affiliation: The Retina Group of Washington, Washington DC Miyake M, Nakao SY, Morino K, et al. Effect of Duration of Macular Detachment on Visual Prognosis after Surgery for Macula-Off Retinal Detachment: Japan-Retinal Detachment Registry. Ophthalmol Retina. 2023;7(5):375-382. doi:10.1016/j.oret.2023.01.014 There is considerable debate regarding the allowable duration of time
- [Four-Year Outcomes in Protocol W](https://vitbucklesociety.org/2023/05/30/four-year-outcomes-in-protocol-w/) - May 2023 Kyle Davis Kovacs, MD Weill Cornell Medicine, New York, NY Maturi RK, Glassman AR, Josic K, Baker CW, Gerstenblith AT, Jampol LM, Meleth A, Martin DF, Melia M, Punjabi OS, Rofagha S, Salehi-Had H, Stockdale CR, Sun JK; DRCR Retina Network. Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept
- [iERM: Immediate Versus Deferred Surgery](https://vitbucklesociety.org/2023/04/02/1456/) - March 2023 Joshua Uhr, MD Location/Affiliation: Retinal and Ophthalmic Consultants, PC Northfield, NJ Al-Khersan H, Shaheen AR, Flynn HW Jr, Smiddy WE. Natural History and Surgical Timing for Idiopathic Epiretinal Membrane. Ophthalmol Retina. 2022 Nov;6(11):978-984. doi: 10.1016/j.oret.2022.02.014. Epub 2022 Mar 8. PMID: 35272083. The authors studied the natural history of idiopathic epiretinal membrane (iERM) and
- [RPD and Higher Risk of Progression to Late AMD](https://vitbucklesociety.org/2023/02/28/rpd-and-higher-risk-of-progression-to-late-amd/) - February 2023 Youning Zhang, MD Location/Affiliation: Los Angeles, Olive View – UCLA Medical Center Agron E, Domalpally A, Cukras C, Clemons TE, Chen Q, Lu Z, Chew EY, Keenan TDL, for the AREDS and AREDS2 Research Group. Ophthalmology 2022;129:1107-1119. Reticular Pseudodrusen: The Third Macular Risk Feature for Progression to Late Age-Related Macular Degeneration. doi: 10.1016/j.ophtha.2022.05.021.
- [Vitrectomy-Associated Endophthalmitis and COVID-19](https://vitbucklesociety.org/2023/04/23/vitrectomy-associated-endophthalmitis-and-covid-19/) - April 2023 Asghar “Abbas” Haider, MD, MBA Southeastern Retina Associates, Chattanooga, TN Sakamoto, Taiji, et al. "Increased incidence of endophthalmitis after vitrectomy relative to face mask wearing during COVID-19 pandemic." British Journal of Ophthalmology (2022). Vitrectomy-associated endophthalmitis is a rare but severe complication that can cause significant visual impairment. Recent reports have highlighted a potential increase
- [Fellow Eye RRD Risk Stratified by Hyaloid Status on OCT at initial RRD Diagnosis](https://vitbucklesociety.org/2023/04/09/fellow-eye-rrd-risk-stratified-by-hyaloid-status-on-oct-at-initial-rrd-diagnosis/) - April 2023 Samir N. Patel, MD Retina Vitreous Consultants Pittsburgh PA Wallsh JO, Langevin ST, Kumar A, Huz J, Falk NS, Bhatnagar P. Fellow Eye Retinal Detachment Risk as Stratified by Hyaloid Status on Optical Coherence Tomography. Ophthalmology. 2023 Feb 9:S0161-6420(23)00105-7. doi: 10.1016/j.ophtha.2023.02.004. Epub ahead of print. PMID: 36773761. In patients with a rhegmatogenous
- [Optimal Timing for RRD Repair](https://vitbucklesociety.org/2023/02/23/optimal-timing-for-rrd-repair/) - February 2023 Written by: Monique Munro, MD, FRCSC Locum with University of Calgary, Section of Ophthalmology Calgary, AB, Canada Sothivannan A, Eshtiaghi A, Dhoot AS, Popovic MM, Garg SJ, Kertes PJ, Muni RH. Impact of the Time to Surgery on Visual Outcomes for Rhegmatogenous Retinal Detachment Repair: A Meta-Analysis. Am J Ophthalmol. 2022 Dec;244:19-29. Visual
- [Drainage Retinotomy is a Risk Factor for Surgical Failure after Pars Plana Vitrectomy in Patients with Primary Uncomplicated Rhegmatogenous Retinal Detachment](https://vitbucklesociety.org/2023/01/18/drainage-retinotomy-is-a-risk-factor-for-surgical-failure-after-pars-plana-vitrectomy-in-patients-with-primary-uncomplicated-rhegmatogenous-retinal-detachment/) - January 2023 Written by: Tamara Lee Lenis, MD PhD NJ Retina Ohara H, Yuasa Y, Harada Y, Hiyama T, Sadahide A, Minamoto A, Hirooka K, Kiuchi Y. DRAINAGE RETINOTOMY IS A RISK FACTOR FOR SURGICAL FAILURE AFTER PARS PLANA VITRECTOMY IN PATIENTS WITH PRIMARY UNCOMPLICATED RHEGMATOGENOUS RETINAL DETACHMENT. Retina. 2022 Dec 1;42(12):2307-2314. doi: 10.1097/IAE.0000000000003608. PMID:
- [Evaluation of Subretinal fluid Drainage Techniques During Pars Plana Vitrectomy for Primary Rhegmatogenous Retinal Detachment - ELLIPSOID Study](https://vitbucklesociety.org/2023/01/03/evaluation-of-subretinal-fluid-drainage-techniques-during-pars-plana-vitrectomy-for-primary-rhegmatogenous-retinal-detachment-ellipsoid-study/) - January 2023 Written by: Priya Vakharia, MD Retina Vitreous Associates of Florida Tampa Bay, FL McKay BR, Bansal A, Kryshtalskyj M, Wong DT, Berger A, Muni RH. Evaluation of Subretinal fluid Drainage Techniques During Pars Plana Vitrectomy for Primary Rhegmatogenous Retinal Detachment-ELLIPSOID Study. Am J Ophthalmol. 2022 Sep;241:227-237. doi: 10.1016/j.ajo.2022.05.008. Epub 2022 May 18. PMID: 35597323. This
- [Air Versus Gas Tamponade for Small- and Medium-Sized Macular Holes](https://vitbucklesociety.org/2023/02/07/air-versus-gas-tamponade-for-small-and-medium-sized-macular-holes/) - February 2023 Written by: Wasim Samara, MD Taylor Retina Center Raleigh, NC Lindtjørn B, Krohn J, Haugstad M, Stene-Johansen I, Austeng D, Basit S, Fossen K, Varhaug P, Kvaløy JT, Forsaa VA. Air versus Sulfur Hexafluoride Gas Tamponade for Small and Medium-Sized Macular Holes: A Randomized Noninferiority Trial. Ophthalmol Retina. 2022 Sep;6(9):828-834. doi: 10.1016/j.oret.2022.04.003. Epub
- [Efficacy and Safety of Biosimilar FYB201 Compared With Ranibizumab in Neovascular Age-Related Macular Degeneration](https://vitbucklesociety.org/2022/12/11/efficacy-and-safety-of-biosimilar-fyb201-compared-with-ranibizumab-in-neovascular-age-related-macular-degeneration/) - December 2022 Written by: Jordan Deaner, MD Mid Atlantic Retina / Wills Eye Hospital Philadelphia, PA Holz FG, Oleksy P, Ricci F, et al. Efficacy and safety of biosimilar FYB201 compared with ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2022;129(1):54-63. Recently the United States Food and Drug Administration (USFDA) approved the first interchangeable biosimilar for use
- [Gas Tamponade for the Prevention of Postoperative Vitreous Hemorrhaging After Diabetic Vitrectomy: A Randomized Clinical Trial](https://vitbucklesociety.org/2022/12/27/gas-tamponade-for-the-prevention-of-postoperative-vitreous-hemorrhaging-after-diabetic-vitrectomy-a-randomized-clinical-trial/) - December 2022 Written by: Jordan Deaner, MD Mid Atlantic Retina / Wills Eye Hospital Philadelphia, PA Rush RB, Velazquez JC, Rosales CR, Rush SW. Gas Tamponade for the Prevention of Postoperative Vitreous Hemorrhaging After Diabetic Vitrectomy: A Randomized Clinical Trial. Am J Ophthalmol. 2022;242:173-180. doi:10.1016/j.ajo.2022.06.015 Disclosures: EyePoint - Consultant, Alimera – Consultant Vitreous hemorrhage (VH)
- [OCT Risk Factors for Development of Atrophy in Eyes with Intermediate Age-Related Macular Degeneration](https://vitbucklesociety.org/2022/12/07/oct-risk-factors-for-development-of-atrophy-in-eyes-with-intermediate-age-related-macular-degeneration/) - November 2022 Written by: Katherine E. Talcott, MD Cole Eye Institute / Cleveland Clinic Hirabayashi K, Yu HJ, Wakatsuki Y, Marion KM, Wykoff CC, Sadda SR. OCT risk factors for development of atrophy in eyes with intermediate age-related macular degeneration. Ophthalmol Retina. 2022;6;S2468-6530(22)00486-9. doi 10.1016/j.oret.2022.09.007. Online ahead of print. While treatments for atrophic age-related macular
- [Embedding Technique versus Conventional Internal Limiting Membrane Peeling for Lamellar Macular Hole with Epiretinal Proliferation](https://vitbucklesociety.org/2022/08/22/embedding-technique-versus-conventional-internal-limiting-membrane-peeling-for-lamellar-macular-hole-with-epiretinal-proliferation/) - August 2022 Written by: Nika Bagheri, MD California Retina Consultants Santa Barbara, CA Kanai M., Sakimoto S., Takahashi S., Nishida K., Maruyama K., Sato S., Sakaguchi H. & Nishida K., Embedding Technique versus Conventional Internal Limiting Membrane Peeling for Lamellar Macular Hole with Epiretinal Proliferation, Ophthalmology Retina (2022), doi: https:// doi.org/10.1016/j.oret.2022.07.009. The purpose of this
- [Postoperative Endophthalmitis in Immediate Sequential Bilateral Cataract Surgery](https://vitbucklesociety.org/2022/05/24/postoperative-endophthalmitis-in-immediate-sequential-bilateral-cataract-surgery/) - May 2022 Written by: Phillip Storey, MD Austin Retina Associates Austin, TX Friling E, Johansson B, Londsteom M, et al. Postoperative endophthalmitis in immediate sequential bilateral cataract surgery: a nationwide registry study.Ophthalmology. 2022;129(1):26-34. Lacy M, Kung T, Owens J, et al. Endophthalmitis rate in immediately sequential versus delayed sequential bilateral cataract surgery within the IRIS registry
- [Cost-Effectiveness Analysis of Intravitreal Aflibercept for the Prevention of Progressive Diabetic Retinopathy](https://vitbucklesociety.org/2022/06/15/cost-effectiveness-analysis-of-intravitreal-aflibercept-for-the-prevention-of-progressive-diabetic-retinopathy/) - June 2022 Written by: Wenlan Zhang, MD Retina Northwest Portland, OR Patel, N. Yannuzzi, N. Lin, J. Smiddy, W. A Cost-Effectiveness Analysis of Intravitreal Aflibercept for the Prevention of Progressive Diabetic Retinopathy. Ophthalmol Retina. 2022;6:213-218. This was a cost-effectiveness analysis based on published data from two recent randomized control trials studying the early treatment of
- [Faricimab and DME: YOSEMITE and RHINE (Phase 3 Trial)](https://vitbucklesociety.org/2022/05/09/faricimab-and-dme-yosemite-and-rhine-phase-3-trial/) - May 2022 Written by: Edward Wood, MD Austin Retina Associates Austin, TX Wykoff, C. C., F. Abreu, A. P. Adamis, and K. Basu. 2022. “Efficacy, Durability, and Safety of Intravitreal Faricimab with Extended Dosing up to Every 16 Weeks in Patients with Diabetic Macular Oedema (YOSEMITE and RHINE): two randomized, double-masked, phase 3 trials. The Lancet.
- [Accuracy of Spectral-Domain OCT of the Macula for Detection of Complete Posterior Vitreous Detachment](https://vitbucklesociety.org/2022/05/02/accuracy-of-spectral-domain-oct-of-the-macula-for-detection-of-complete-posterior-vitreous-detachment/) - May 2022 Written by: Daniel Su, MD Retina-Vitreous Associates Medical Group Los Angeles, CA Hwang ES, Kraker JA, Griffin KJ, Sebag J, Weinberg DV, Kim JE. Accuracy of Spectral-Domain OCT of the Macula for Detection of Complete Posterior Vitreous Detachment. Ophthalmol Retina. 2020 Feb;4(2):148-153. Posterior vitreous detachment (PVD) is the age-related separation of vitreous from
- [TENAYA and LUCERNE: Phase 3 Trials of Intravitreal Faricimab up to Every 16 Weeks for Neovascular Age-related Macular Degeneration](https://vitbucklesociety.org/2022/04/26/tenaya-and-lucerne-phase-3-trials-of-intravitreal-faricimab-up-to-every-16-weeks-for-neovascular-age-related-macular-degeneration/) - April 2022 Written by: Mohsin H. Ali, MD Retina Group of Washington Washington D.C. Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Efficacy, durability,
- [Safety Outcomes of Brolucizumab in Neovascular Age-related Macular Degeneration: Results from the IRIS Registry and Komodo Healthcare Map](https://vitbucklesociety.org/2022/04/18/safety-outcomes-of-brolucizumab-in-neovascular-age-related-macular-degeneration-results-from-the-iris-registry-and-komodo-healthcare-map/) - April 2022 Written by: Akshay Thomas, M.D. Tennessee Retina Nashville, TN Khanani AM, Zarbin MA, Barakat MR, et al. Safety outcomes of brolucizumab in neovascular age-related macular degeneration: results from the iris registry and komodo healthcare map. JAMA Ophthalmol. 2022;140(1):20-28. Treatment options for wet AMD include off-label use of bevacizumab or use of an FDA-approved
- [Vitrectomy for Symptomatic Asteroid Hyalosis](https://vitbucklesociety.org/2022/04/08/vitrectomy-for-symptomatic-asteroid-hyalosis/) - April 2022 Written by: Vlad Matei, M.D. Rocky Mountain Retina Associates Boulder, CO Marlow E, Hassan T, Faia L, et al. Vitrectomy for symptomatic asteroid hyalosis. J Vitreoretin Dis 2021;5(5):420-424. Asteroid hyalosis (AH) is a common and benign degeneration consisting of calcium- and lipid-rich opacities, termed asteroid bodies (ABs), accumulating in the vitreous gel. Until
- [Representation of Women in Ophthalmology Subspecialty Societies over 20 Years](https://vitbucklesociety.org/2022/03/29/representation-of-women-in-ophthalmology-subspecialty-societies-over-20-years/) - March 2022 Written by: Katherine E. Talcott, MD Cole Eye Institute Cleveland Clinic Azad AD, Chandramohan A, Li AS, Rosenblatt TR, Reeves M-GR, Pasricha MV, Ludwig CA, Nguyen A, Winges KM, Wang SY, Pan CK, Moss HE, Do DV, Fountain TR, Kossler AL, Representation of Women in Ophthalmology Subspecialty Societies over 20 Years, Ophthalmology (2022),
- [Impact of Residual Subretinal Fluid Volumes on Treatment Outcomes in a Subretinal Fluid-Tolerant Treat-and-Extend Regimen](https://vitbucklesociety.org/2022/03/29/impact-of-residual-subretinal-fluid-volumes-on-treatment-outcomes-in-a-subretinal-fluid-tolerant-treat-and-extend-regimen/) - March 2022 Written by: Maxwell Stem, MD Pennsylvania Retina Specialists, PC Gretchenig C, Reiter GS, Riedl S, Arnold J, Guymer R, Gerendas BS, Bogunovic H, Schmidt-Erfurth U. Impact of Residual Subretinal Fluid Volumes on Treatment Outcomes in a Subretinal Fluid-Tolerant Treat-and-Extend Regimen. Retina. 2021;41(11):2221-2228. The axiom that the goal of anti-VEGF therapy is to completely
- [ARCHWAY: Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration](https://vitbucklesociety.org/2022/02/28/archway-randomized-phase-3-trial-of-the-port-delivery-system-with-ranibizumab-for-neovascular-age-related-macular-degeneration/) - February 2022 Written by: Nika Bagheri, MD California Retina Consultants and Research Foundation Santa Barbara, CA Holekamp NM, Campochiaro PA, Chang M, Miller D, Pieramici D, Adamis AP, Brittain C, Evans E, Kaufman D, Maass KF, Patel S, Ranade S, Singh N, Barteselli G, Regillo C, on behalf of all Archway Investigators. ARCHWAY: Randomized
- [Outer Retinal Folds Following Pars Plana Vitrectomy vs. Pneumatic Retinopexy for Retinal Detachment Repair: Post Hoc Analysis from PIVOT](https://vitbucklesociety.org/2022/02/16/outer-retinal-folds-following-pars-plana-vitrectomy-vs-pneumatic-retinopexy-for-retinal-detachment-repair-post-hoc-analysis-from-pivot/) - February 2022 Written by: Christian Sanfilippo, MD The Retina Partners Los Angeles, CA Lee WW, Bansal A, Sadda S, Sarraf D, Berger AR, Wong DT, Kertes PJ, Kohly RP, Hillier RJ, Muni RH. Outer Retinal Folds Following Pars Plana Vitrectomy vs Pneumatic Retinopexy for Retinal Detachment Repair: Post Hoc Analysis from PIVOT. Ophthalmol Retina. 2021
- [Laser Treatment after Minimized Eye Movement for Repair of Retinal Detachment](https://vitbucklesociety.org/2022/02/08/laser-treatment-after-minimized-eye-movement-for-repair-of-retinal-detachment/) - February 2022 Assistant ProfessorVanderbilt Eye InstituteNashville, TN Kokame GT, Yee S, Omizo JN, Villanueva L, Liu J. Laser Treatment after Minimized Eye Movement for Repair of Retinal Detachment. Ophthalmol Retina. 2021 Sep;5(9):939-941. doi: 10.1016/j.oret.2021.01.014. Epub 2021 Jan 30. PMID: 33529816. Retinal detachment repair is typically performed via three potential procedures: pneumatic retinopexy, scleral buckling, and
- [Outcomes of Infectious Endophthalmitis in Patients with Systemic Antibiotic Allergies to Penicillins, Cephalosporins or Vancomycin](https://vitbucklesociety.org/2022/01/26/outcomes-of-infectious-endophthalmitis-in-patients-with-systemic-antibiotic-allergies-to-penicillins-cephalosporins-or-vancomycin/) - January 2022 Written by: Rehan Hussain, MDRetina Health InstituteElgin, IL Meyer BI, Berry DE, Cribbs BE, et al. Outcomes of Infectious Endophthalmitis in Patients with Systemic Antibiotic Allergies to Penicillins, Cephalosporins, or Vancomycin. Ophthalmol Retina 2021 Sep;5(9):901-909 Infectious endophthalmitis is a rare but potentially visually devastating issue that requires prompt diagnosis and treatment, typically with
- [Telehealth-based Eye Care During the COVID-19 Pandemic: Utilization, Safety, and the Patient Experience](https://vitbucklesociety.org/2022/01/18/telehealth-based-eye-care-during-the-covid-19-pandemic-utilization-safety-and-the-patient-experience/) - Written by: Jaya Badhwar Kumar, MDFlorida Retina InstituteOrlando, FL January 2022 Newman-Casey, Paula Anne et al. Telehealth-based Eye Care During the COVID-19 Pandemic: Utilization, Safety, and the Patient Experience. Am J Ophthal, 2021. 230: 234 –242. In the era of a global pandemic, the demand for telehealth services has expanded across all fields of medicine
- [Delayed Retinal Breaks and Detachments after Acute Posterior Vitreous Detachment](https://vitbucklesociety.org/2020/04/01/delayed-retinal-breaks-and-detachments-after-acute-posterior-vitreous-detachment/) - Written by: Prethy Rao, MD MPH Uhr JH, Obeid A, Wibbelsman et al. Delayed Retinal Breaks and Detachments after Acute Posterior Vitreous Detachment. Ophthalmology Volume 127, Number 4, April 2020. Posterior vitreous detachment (PVD) is one of the most common vitreoretinal diagnoses that the retina specialist encounters in his or her day-to-day practice. Although the typical
- [Protocol V Summary](https://vitbucklesociety.org/2019/06/21/protocol-v-summary/) - Written by: Judy Chen, MD Baker CW, Glassman AR, Beaulieu WT, et al. Effect of Initial Management of Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients with Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial. JAMA 2019 Apr 29 [Epub ahead of print].
- [PIVOT: Pneumatic Retinopexy vs. Vitrectomy for Primary RRD](https://vitbucklesociety.org/2019/06/24/pivot-pneumatic-retinopexy-vs-vitrectomy-for-primary-rrd/) - Written by: Maxwell S. Stem, MD Hillier RJ, Felfeli T, Berger AR, et al. The Pneumatic Retinopexy versus Vitrectomy for the Management of Primary Rhegmatogenous Retinal Detachment Outcomes Randomized Trial (PIVOT). Ophthalmology. 2019;126(4):531-539. The optimal management of a primary, uncomplicated rhegmatogenous retinal detachment (RRD) is a matter of some debate among vitreoretinal surgeons. Recently, Hillier
- [Anti-VEGF Therapy and Associated Risk of Serious Cardiovascular Events](https://vitbucklesociety.org/2019/06/24/anti-vegf-therapy-and-associated-risk-of-serious-cardiovascular-events/) - Written by: Judy J. Chen, MD Dalvin LA, Starr MR, AbouChehade JE, et al. Association of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy with Risk of Stroke, Myocardial Infarction, and Death in Patients with Exudative Age-Related Macular Degeneration. JAMA Ophthalmol. 2019;137(5):483-490. Ever since intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents became the mainstay of
- [Macular Hole Hydrodissection for Persistent, Chronic, and Large Macular Holes](https://vitbucklesociety.org/2019/06/24/macular-hole-hydrodissection-for-persistent-chronic-and-large-macular-holes/) - Written by: Maxwell S. Stem, MD Felfeli T, Mandelcorn ED. MACULAR HOLE HYDRODISSECTION: Surgical Technique for the Treatment of Persistent, Chronic, and Large Macular Holes. Retina. 2019;39(4):743-752. While the vast majority of full thickness macular holes (MH) close with standard vitrectomy surgery, peeling of the internal limiting membrane (ILM), and gas tamponade, there exists a
- [Efficacy of topical timolol eye drops for the treatment of diabetic macular edema](https://vitbucklesociety.org/2019/07/09/efficacy-of-topical-timolol-eye-drops-for-the-treatment-of-diabetic-macular-edema/) - Written by: Prethy Rao, MD Falavarjani K.G., Hadi Y., Habibi A., Anvari P., Modarres M., Parvaresh M.M.,Jafari S. & Alemzadeh S.A. Ophthalmol Retina. 2019 Jun;3(6):538-539 We live in an exciting time in retina with new pathway drugs being rolled into clinical trials and markets—from TIE2 receptors, DARPins, smaller VEGF antibody fragments (conbercerpt, brolicizumab) etc—for both macular
- [Non-supine Positioning after Macular Hole Surgery](https://vitbucklesociety.org/2019/07/22/non-supine-positioning-after-macular-hole-surgery/) - Written by: Katherine E. Talcott, MD Lindtjorn B, Krohn J Austeng D et al. Nonsupine positioning after macular hole surgery: a prospective multicenter study. Ophthalmol Retina. 2019 May;3(5):388-92. Macular hole (MH) surgical repair typically involves the release of tangential traction on the retina by lifting the hyaloid, removal of the internal limiting membrane, epiretinal membrane,
- [Intravitreal Gas Injection with Laser Photocoagulation for Highly Myopic Foveoschisis](https://vitbucklesociety.org/2019/07/26/intravitreal-gas-injection-with-laser-photocoagulation-for-highly-myopic-foveoschisis/) - Written by: Prethy Rao, MD Zhu X, Shen P, Li C, Li H, Huang H, Shi K, Wang L, Zhang X, Lu L. Retina. 2019 Jul;39(7):1305-1311 Myopic macular foveoschisis in patients is often a daunting clinical finding in many practices as progression and surgical outcomes are often variable. While present in 15-20% of myopic patients,
- [Safety of 6000 Intravitreal Dexamethasone Implants](https://vitbucklesociety.org/2019/07/29/safety-of-6000-intravitreal-dexamethasone-implants/) - Written by: Katherine E. Talcott, MD Rajesh B, Zarranz-Ventura J, Fung AT et al. Safety of 6000 intravitreal dexamethasone implants. Br J Ophthalmol. 2019 April 30. [Epub ahead of print] Corticosteroids, including the intravitreal dexamethasone implant, are used to treat macular edema from multiple etiologies. Clinical trials have revealed an increase in IOP and cataract
- [Two-Year Risk of Exudation in Eyes with Non-Exudative, Neovascular AMD Detected with Swept Source OCTA](https://vitbucklesociety.org/2019/08/22/two-year-risk-of-exudation-in-eyes-with-non-exudative-neovascular-amd-detected-with-swept-source-octa/) - Written by: Brian K. Do, MD August 2019 Yang J, Zhang Q, Motulsky EH, Thulliez M, Shi Y, Lyu C, de Sisternes L, Durbin MK, Feuer W, Wang RK, Gregori G, Rosenfeld PJ. Two-Year Risk of Exudation in Eyes with Non-Exudative AMD and Subclinical Neovascularization Detected with Swept Source OCT Angiography. American Journal of Ophthalmology
- [FLUID Study 24-Month Results: Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen](https://vitbucklesociety.org/2019/08/28/fluid-study-24-month-results-tolerating-subretinal-fluid-in-neovascular-age-related-macular-degeneration-treated-with-ranibizumab-using-a-treat-and-extend-regimen/) - Written by: Christopher Aderman, MD August 2019 Robyn H. Guymer, MBBS, PhD, Caroline M. Markey, PhD, Ian L. McAllister, MBBS, PhD, Mark C. Gillies, MBBS, PhD, Alex P. Hunyor, MBBS, Jennifer J. Arnold, MBBS, on behalf of the FLUID Investigators. Ophthalmology. Volume 126, Number 5, May 2019 Analysis of the CATT, VIEW, and HARBOR studies
- [The Port Delivery System with Ranibizumab for nAMD: Results from the Phase 2 LADDER Study](https://vitbucklesociety.org/2019/09/04/the-port-delivery-system-with-ranibizumab-for-namd-results-from-the-phase-2-ladder-study/) - Written by: Joshua D. Levinson, MD September 2019 Campochiaro PA, Marcus DM, Awh CC, et al. The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial. Ophthalmology. 2019 Aug;126(8):1141-1154 Intravitreal anti-vascular endothelial growth factor (VEGF) therapy has revolutionized the treatment of neovascular age-related macular degeneration
- [Subthreshold Nanosecond Laser Intervention in Age-Related Macular Degeneration](https://vitbucklesociety.org/2019/09/06/subthreshold-nanosecond-laser-intervention-in-age-related-macular-degeneration/) - Written by: Brian K. Do, MD September 2019 Guymer RH, Wu Z, Hodgson LA, et al. Subthreshold Nanosecond Laser Intervention in Age-Related Macular Degeneration: The LEAD Randomized Controlled Clinical Trial. Ophthalmology. 2019 Jun;126(6):829-838. doi: 10.1016/j.ophtha.2018.09.015. Epub 2018 Sep 20. Rosenfeld PJ, Feuer WJ. Warning: Do not Treat Intermediate AMD with Laser Therapy. Ophthalmology. 2019 Jun;126(6):839-840. doi: 10.1016/j.ophtha.2018.12.016.
- [HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration](https://vitbucklesociety.org/2019/09/11/hawk-and-harrier-phase-3-multicenter-randomized-double-masked-trials-of-brolucizumab-for-neovascular-age-related-macular-degeneration/) - Written by: Christopher Aderman, MD September 2019 Pravin U. Dugel, MD, Adrian Koh, MD, FRCS, Yuichiro Ogura, MD, Glenn J. Jaffe, MD, Ursula Schmidt-Erfurth, MD, David M. Brown, MD, Andre V. Gomes, MD, PhD, James Warburton, MBBS, Andreas Weichselberger, PhD, Frank G. Holz, MD, on behalf of the HAWK and HARRIER Study Investigators. Ophthalmology. 2019 Apr 12.
- [Phenotypic Spectrum of Pentosan Polysulfate Sodium–Associated Maculopathy: A Multicenter Study](https://vitbucklesociety.org/2019/10/01/phenotypic-spectrum-of-pentosan-polysulfate-sodium-associated-maculopathy-a-multicenter-study/) - Written by: Joshua D. Levinson, MD September 2019 Adam M. Hanif, MD; Stephen T. Armenti, MD, PhD; Stanford C. Taylor, MD, et al. Phenotypic Spectrum of Pentosan Polysulfate Sodium–Associated Maculopathy A Multicenter Study. JAMA Ophthalmol. Sept 2019. Pentosan polysulfate sodium (brand name: Elmiron) is used to treat interstitial cystitis (IC), a chronic pain syndrome of
- [Rhegmatogenous Retinal Detachment in Children: Clinical Factors Predictive of Successful Surgical Repair](https://vitbucklesociety.org/2019/10/11/rhegmatogenous-retinal-detachment-in-children-clinical-factors-predictive-of-successful-surgical-repair/) - Written by: Vlad Matei, MD October 2019 Smith JM, Ward LT, Townsend JH, et al. Rhegmatogenous retinal detachment in children: clinical factors predictive of successful surgical repair. Ophthalmology 2019;126:1263-1270. The literature devoted to pediatric rhegmatogenous retinal detachment (RRD) is relatively scarce, but we know that RRD in children is potentially more challenging to manage than
- [Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs. Aflibercept vs. Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial by the LEAVO Study Group](https://vitbucklesociety.org/2019/10/17/clinical-effectiveness-of-intravitreal-therapy-with-ranibizumab-vs-aflibercept-vs-bevacizumab-for-macular-edema-secondary-to-central-retinal-vein-occlusion-a-randomized-clinical-trial-by-the-leavo/) - Written by: Avni P. Finn, MD October 2019 Hykin P, Prevost AT, Vasconcelos JC, et al. Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial. JAMA Ophthalmol. Published online August 29, 2019. doi:10.1001/jamaophthalmol.2019.3305 Visual impairment in central retinal vein occlusion (CRVO) due to
- [Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2](https://vitbucklesociety.org/2019/10/29/effect-of-ciliary-neurotrophic-factor-on-retinal-neurodegeneration-in-patients-with-macular-telangiectasia-type-2/) - Written by: Akshay S. Thomas, MD October 2019 Chew EY, Clemons TE, Jaffe GJ, et al. Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical Trial. Ophthalmology. 2019;126(4):540-549. Macular telangiectasia type 2 (MacTel 2) is an idiopathic condition without available treatment options which results in slowly
- [A Human Amniotic Membrane Plug to Promote Retinal Break Repair and Recurrent Macular Hole Closure](https://vitbucklesociety.org/2019/11/06/a-human-amniotic-membrane-plug-to-promote-retinal-break-repair-and-recurrent-macular-hole-closure/) - Written by: Mohsin H. Ali, MD October 2019 Rizzo S, Caporossi T, Tartaro R, Finocchio L, Franco F, Barca F, et al. A Human Amniotic Membrane Plug to Promote Retinal Breaks Repair and Recurrent Macular Hole Closure. Retina 2019;39. Chronic, large macular holes that are refractory to initial, conventional surgical approaches (e.g. pars plana vitrectomy,
- [Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials](https://vitbucklesociety.org/2019/11/22/efficacy-safety-and-durability-of-voretigene-neparvovec-rzyl-in-rpe65-mutation-associated-inherited-retinal-dystrophy-results-of-phase-1-and-3-trials/) - Written by: Rehan M. Hussain, MD November 2019 Maguire, AM, Russell S, Wellman JA. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials. Ophthalmology 2019 Sep;126(9):1273-1285. doi: 10.1016/j.ophtha.2019.06.017. Published online Jun 22, 2019. Voretigene neparvovec (VN) is a non-replicating adeno-associated virus (AAV), which has
- [Cost Analysis of Pneumatic Retinopexy versus Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment](https://vitbucklesociety.org/2019/12/02/cost-analysis-of-pneumatic-retinopexy-versus-pars-plana-vitrectomy-for-rhegmatogenous-retinal-detachment/) - Written by: Daniel Su, MD November 2019 Elhusseiny AM, Yannuzzi NA, Smiddy WE. Cost Analysis of Pneumatic Retinopexy versus Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment. Ophthalmol Retina 2019;3:956–961 Rhegmatogenous retinal detachment (RRD) may result in significant and permanent vision loss. Many studies have looked at outcomes of various surgical techniques in achieving single surgical
- [Single-Port Vitrectomy and “Oleodelamination” for the Management of Retinal Detachment Complicated by Proliferative Vitreoretinopathy](https://vitbucklesociety.org/2019/12/08/single-port-vitrectomy-and-oleodelamination-for-the-management-of-retinal-detachment-complicated-by-proliferative-vitreoretinopathy/) - Written by: Edward H. Wood, MD November 2019 Svasti-Salee CR, Dawkins RCH, Poulson AV, Snead MP. Single-Port Vitrectomy and “Oleodelamination” for the Management of Retinal Detachment Complicated by Proliferative Vitreoretinopathy. Retina. 2019;39 Suppl 1:S125-S128. Open Access Article Link: https://journals.lww.com/retinajournal/Fulltext/2019/10001/Single_Port_Vitrectomy_and__Oleodelamination__for.30.aspx#pdf-link Open Access Video Link: https://d047c2cddb.site.internapcdn.net/permalink/iae/a/iae_2017_04_20_snead_216-1031_sdc1.mp4 In this surgical technique special edition of RETINA: The Journal of
- [Predictors of Endophthalmitis after Intravitreal Injection: A Multivariable Analysis Based on Injection Protocol and Povidone Iodine Strength](https://vitbucklesociety.org/2019/12/20/predictors-of-endophthalmitis-after-intravitreal-injection-a-multivariable-analysis-based-on-injection-protocol-and-povidone-iodine-strength/) - Written by: Durga S. Borkar, MD December 2019 Stem MS, Rao P, Lee IJ, Woodward MA, Faia LJ, Wolfe JA, Capone A Jr, Covert D, Dass AB, Drenser KA, Garretson BR, Hassan TS, Margherio A, Oh KT, Raephaelian PV, Randhawa S, Sneed S, Trese MT, Yedavally S, Williams GA, Ruby AJ. Predictors of Endophthalmitis after
- [Aflibercept-Related Sterile Intraocular Inflammation Outcomes](https://vitbucklesociety.org/2019/12/24/aflibercept-related-sterile-intraocular-inflammation-outcomes/) - Written by: Priya Sharma Vakharia, MD December 2019 Greenberg JP, Belin P, Butler J, et al. Aflibercept-Related Sterile Intraocular Inflammation Outcomes. Ophthalmology Retina 2019;3: 753-9. Sterile intraocular inflammation after intravitreal injections is a well-known but rare side effect. Sterile inflammation has been reported with all anti-vascular endothelial growth factor (VEGF) injections, typically occurring in clusters.
- [Long-Term Visual Outcomes and Clinical Features After Anti-Vascular Endothelial Growth Factor Injection-Related Endophthalmitis](https://vitbucklesociety.org/2020/01/06/long-term-visual-outcomes-and-clinical-features-after-anti-vascular-endothelial-growth-factor-injection-related-endophthalmitis/) - Written by: Andrew Tye, MD January 2020 Rayess N, Obeid A, Storey PP, et al. Long-Term Visual Outcomes and Clinical Features After Anti-Vascular Endothelial Growth Factor Injection-Related Endophthalmitis. Retina 2019;39:2070-2076. In the era of anti-vascular endothelial growth factor (anti-VEGF) therapy for retinal disease, endophthalmitis is arguably the most dreaded post-procedural complication for retina specialists. Fortunately,
- [Prevalence, Risk, and Genetic Association of Reticular Pseudodrusen in Age-related Macular Degeneration](https://vitbucklesociety.org/2020/01/13/prevalence-risk-and-genetic-association-of-reticular-pseudodrusen-in-age-related-macular-degeneration/) - Written by: Andrew Tye, MD January 2020 Domalpally AD, Agron E, Pak JW, et al. Prevalence, Risk, and Genetic Association of Reticular Pseudodrusen in Age-related Macular Degeneration (Age-Related Eye Disease Study 2 Report 21). Ophthalmology 2019; 126: 1659-66. In recent years, reticular pseudodrusen (RPD) have become their own distinct category from drusen; histopathology has confirmed
- [Pars Plana Vitrectomy for the Treatment of Tractional and Degenerative Lamellar Macular Holes: Functional and Anatomical Results](https://vitbucklesociety.org/2020/01/22/pars-plana-vitrectomy-for-the-treatment-of-tractional-and-degenerative-lamellar-macular-holes-functional-and-anatomical-results/) - Written by: Musa R. Abdelaziz, MD January 2020 Figueroa M, Govetto A, Steel D, et al. Pars Plana Vitrectomy for the Treatment of Tractional and Degenerative Lamellar Macular Holes: Functional and Anatomical Results. Retina, Nov 2019; 39: 2090 – 2098. The diagnosis of lamellar macula hole (LMH) was first described by Gass in 1976 and
- [Impact of Periocular Vibration on Pain Perceived during Intravitreal Injections](https://vitbucklesociety.org/2020/01/31/impact-of-periocular-vibration-on-pain-perceived-during-intravitreal-injections/) - Written by: Philip P. Storey, MD January 2020 Adam MK, Zheng CX, Fineman MS. Impact of Periocular Vibration on Pain Perceived during Intravitreal Injections. Ophthalmol Retina. 2020; 4(1): 113-115. “Cross my heart and hope to die, stick a needle in my eye…” While it is unclear if the phrase above originated as a children’s poem from
- [The Relative Impact of Patient, Physician, and Geographic Factors on Variation in Primary Rhegmatogenous Retinal Detachment Management](https://vitbucklesociety.org/2020/02/05/the-relative-impact-of-patient-physician-and-geographic-factors-on-variation-in-primary-rhegmatogenous-retinal-detachment-management/) - Written by: Jaya B. Kumar, MD February 2020 Vail D, Pershing S, Reeves,M, et al. The Relative Impact of Patient, Physician, and Geographic Factors on Variation in Primary Rhegmatogenous Retinal Detachment Management. Ophthalmology 2020; 127: 97-106. Rhegmatogenous Retinal Detachment (RRD) is one of the most common surgical diagnoses encountered by retina specialists. While there are
- [Association of Rhegmatogenous Retinal Detachment and Outcome With the Day of the Week That Patients Undergo a Repair or Receive a Diagnosis](https://vitbucklesociety.org/2020/02/13/association-of-rhegmatogenous-retinal-detachment-and-outcome-with-the-day-of-the-week-that-patients-undergo-a-repair-or-receive-a-diagnosis/) - Written by: Christian J. Sanfilippo, MD February 2020 Vail D, Pan C, Pershing S, Mruthyunjaya P. Association of Rhegmatogenous Retinal Detachment and Outcome With the Day of the Week That Patients Undergo a Repair or Receive a Diagnosis. JAMA Ophthalmol. 2019 Dec 19. doi: 10.1001/jamaophthalmol.2019.5300 Rhegmatogenous retinal detachment (RRD) is a sight threatening disease that
- [Quantitative Optical Coherence Tomography Angiography Features For Objective Classification And Staging Of Diabetic Retinopathy](https://vitbucklesociety.org/2020/03/03/quantitative-optical-coherence-tomography-angiography-features-for-objective-classification-and-staging-of-diabetic-retinopathy/) - Written by: Nika Bagheri, MD March 2020 Alam M, Zhang Y, Lim JI, Chan RVP, Yang M, Yao X. Quantitative Optical Coherence Tomography Angiography Features for Objective Classification and Staging OF Diabetic Retinopathy. Retina. 2020 Feb;40(2):322-332. doi: 10.1097/IAE.0000000000002373. The evaluation and management of diabetic eye disease is undergoing a paradigm shift, and it could not come soon enough. With diabetic retinopathy a
- [Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration](https://vitbucklesociety.org/2020/03/10/complement-c3-inhibitor-pegcetacoplan-for-geographic-atrophy-secondary-to-age-related-macular-degeneration/) - Written by: Mehnaz Khan, MD March 2020 Liao DS, Grossi FV, El Mehdi D, et al. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2020 Feb;127(2):186-195. doi: 10.1016/j.ophtha.2019.07.011. Epub 2019 Jul 16. Geographic atrophy (GA), a late stage manifestation of age related macular degeneration is an irreversible cause
- [Long-Term Follow-Up of Efficacy and Safety of YAG Vitreolysis for Symptomatic Weiss Ring Floaters](https://vitbucklesociety.org/2020/03/22/long-term-follow-up-of-efficacy-and-safety-of-yag-vitreolysis-for-symptomatic-weiss-ring-floaters/) - Written by: Maxwell S. Stem, MD March 2020 Shah CP, Heier JS. Long-Term Follow-Up of Efficacy and Safety of YAG Vitreolysis for Symptomatic Weiss Ring Floaters. Ophthalmic Surg Lasers Imaging Retina. 2020;51:85-88. Vitreous floaters are a common complaint among patients who visit a vitreoretinal specialist. Management options for symptomatic vitreous floaters include observation, pars plana
- [Effect of Gas Tamponade on IOL Position and Refractive Error after Phacovitrectomy](https://vitbucklesociety.org/2020/04/08/effect-of-gas-tamponade-on-iol-position-and-refractive-error-after-phacovitrectomy/) - Written by: Katherine E. Talcott, MD Shiraki N, Wakabayashi T, Sakaguchi H, Nishida K. Effect of Gas Tamponade on the Intraocular Lens Position and Refractive Error after Phacovitrectomy: A Swept-Source Anterior Segment OCT Analysis. Ophthalmology. 2020;127:511-5. Phacovitrectomy, or combined phacoemulsification, intraocular lens implant (IOL) implantation, and pars plana vitrectomy (PPV), can be used over PPV
- [Timing Influence of Outcomes of Vitrectomy for Open-globe Injury](https://vitbucklesociety.org/2020/04/20/timing-influence-of-outcomes-of-vitrectomy-for-open-globe-injury/) - Written by: Judy Chen, MD April 2020 He Y, Zhang L, Wang F, et al. Timing influence of outcomes of vitrectomy for open-globe injury: A prospective randomized comparative study. Retina April 2020; 40:725-734. Ocular trauma is still one of the leading causes of blindness and visual impairment worldwide. Many incidences of open-globe injury involve damage
- [Effect of Adjuvant Topical Dorzolamide-Timolol vs Placebo in Neovascular Age-Related Macular Degeneration](https://vitbucklesociety.org/2020/04/27/effect-of-adjuvant-topical-dorzolamide-timolol-vs-placebo-in-neovascular-age-related-macular-degeneration/) - Written by: Jeremy Lavine, MD, PhD April 2020 Hsu J, Patel SN, Wolfe JD, et al. Effect of Adjuvant Topical Dorzolamide-Timolol vs Placebo in Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2020 Apr 2. doi: 10.1001/jamaophthalmol.2020.0724. [Epub ahead of print] Anti-vascular endothelial growth factor (VEGF) therapy is the gold standard for neovascular age-related macular degeneration (nvAMD). Despite monthly injections,
- [Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis](https://vitbucklesociety.org/2020/05/06/efficacy-and-safety-of-suprachoroidal-cls-ta-for-macular-edema-secondary-to-noninfectious-uveitis/) - Written by: Joshua D. Levinson, MD May 2020 Yeh S, Khurana RN, Shah M, et al. Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial [published online ahead of print, 2020 Jan 10]. Ophthalmology. 2020;S0161-6420(20)30011-7. doi:10.1016/j.ophtha.2020.01.006 Noninfectious uveitis (NIU) may impair vision due to macular edema and intraocular
- [Effect of Face-Down Positioning vs Support-the-Break Positioning After Macula-Involving Retinal Detachment Repair](https://vitbucklesociety.org/2020/05/13/effect-of-face-down-positioning-vs-support-the-break-positioning-after-macula-involving-retinal-detachment-repair/) - Written by: Avni P. Finn, MD May 2020 Casswell EJ, Yorston D, Lee E, et al. Effect of Face-Down Positioning vs Support-the-Break Positioning After Macula-Involving Retinal Detachment Repair: The PostRD Randomized Clinical Trial. JAMA Ophthalmol. Published online April 16, 2020. There is a lack of consensus among vitreoretinal surgeons in regard to the optimal positioning for patients after
- [Efficacy of Macular Hole Surgery in Patients with Idiopathic Macular Telangiectasia Type 2](https://vitbucklesociety.org/2020/05/24/efficacy-of-macular-hole-surgery-in-patients-with-idiopathic-macular-telangiectasia-type-2/) - Written by: Akshay S. Thomas, MD May 2020 Miller AG, Chandra R, Pophal C, Schartman JP, Hornik JH, Miller DG. Efficacy of Macular Hole Surgery in Patients with Idiopathic Macular Telangiectasia Type 2. Ophthalmol Retina. 2020;4(5):494-497. Idiopathic macular telangiectasia (IMT) type 2 is a neurodegenerative retinal disorder that can occasionally lead to full-thickness macular hole
- [Long-term Outcomes After Macular Hole Surgery](https://vitbucklesociety.org/2020/06/02/long-term-outcomes-after-macular-hole-surgery/) - Written by: Vlad Matei, MD June 2020 Elhusseiny AM, Schwartz SG, Flynn HW Jr, Smiddy WE. Long-term outcomes after macular hole surgery. Ophthalmol Retina 2020;4(4):369-376. Best-corrected visual acuity (BCVA) can continue to improve during at least the first year after pars plana vitrectomy (PPV) with internal limiting membrane (ILM) peeling for idiopathic full-thickness macular hole
- [Facedown Positioning Following Surgery for Large Full-Thickness Macular Hole: Summary of a Randomized Clinical Trial and Invited Commentary](https://vitbucklesociety.org/2020/06/16/facedown-positioning-following-surgery-for-large-full-thickness-macular-hole-summary-of-a-randomized-clinical-trial-and-invited-commentary/) - Written by: Rehan M. Hussain, MD June 2020 Pasu S, Bell L, Zenasni Z, et al; The Positioning in Macular Hole Surgery (PIMS) Study Group. Facedown positioning following surgery for large full-thickness macular hole: a multicenter randomized clinical trial. JAMA Ophthalmol. Published online May 7, 2020. doi:10.1001/jamaophthalmol. 2020.0987 Smiddy WE, Flynn HW Jr, Vanner EA.
- [Autologous Retinal Transplant for Refractory Macular Holes: Multicenter International Collaborative Study Group](https://vitbucklesociety.org/2020/06/28/august-retinal-transplant-for-refractory-macular-holes/) - Written by: Daniel Su, MD June 2020 Grewal DS, Charles S, Parolini B, Kadonosono K, Mahmoud TH. Autologous Retinal Transplant for Refractory Macular Holes: Multicenter International Collaborative Study Group. Ophthalmology 2019 Oct;126(10):1399-1408 Single surgery success rates are high for primary macular holes and are often reported to be higher than 90%. Modern techniques typically involve
- [Primary Retinal Detachment Outcomes Study: Pseudophakic Retinal Detachment Outcomes](https://vitbucklesociety.org/2020/07/07/primary-retinal-detachment-outcomes-study-pseudophakic-retinal-detachment-outcomes/) - Written by: Priya Sharma Vakharia, MD July 2020 Joseph DP, Ryan EH, Ryan CM, et al. Primary Retinal Detachment Outcomes Study: Pseudophakic Retinal Detachment Outcomes. Ophthalmology 2020. Online ahead of print. This study is part 3 of the PRO (Primary Retinal Detachment Outcomes) Study. Part 3 specifically looks at outcomes of pseudophakic retinal detachments treated
- [Fovea-Sparing Versus Standard Internal Limiting Membrane Peeling for Myopic Traction Maculopathy](https://vitbucklesociety.org/2020/07/17/fovea-sparing-versus-standard-internal-limiting-membrane-peeling-for-myopic-traction-maculopathy/) - Written by: Musa R. Abdelaziz, MD July 2020 Nobuhiko Shiraki N, Wakabayashi T, Ikuno Y, et al. Fovea-Sparing Versus Standard Internal Limiting Membrane Peeling for Myopic Traction Maculopathy: A Study of 102 Consecutive Cases. Ophthalmol Retina. 2020 May 26; S2468-6530(20)30208-6. doi: 10.1016/j.oret.2020.05.016. Myopic traction maculopathy is a major source of visual impairment in eyes with
- [Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease 2019 (COVID-19) Patients](https://vitbucklesociety.org/2020/08/01/assessing-viral-shedding-and-infectivity-of-tears-in-coronavirus-disease-2019-covid-19-patients/) - Written by: Philip P. Storey, MD August 2020 Ivan Yu Jun Seah, Danielle E. Anderson, Adrian Eng Zheng Kang, Linfa Wang, Pooja Rao, Barnaby Edward Young, David Chien Lye, Rupesh Agrawal. Ophthalmology. March 24, 2020. Published:March 24, 2020 DOI:https://doi.org/10.1016/j.ophtha.2020.03.026 With the emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), new questions regarding the safety of
- [Disease course in patients with pentosan polysulfate sodium–associated maculopathy after drug cessation](https://vitbucklesociety.org/2020/08/25/disease-course-in-patients-with-pentosan-polysulfate-sodium-associated-maculopathy-after-drug-cessation/) - Written by: Christian J. Sanfilippo, MD August 2020 Shah R, Simonett JM, Lyons RJ, Rao RC, Pennesi ME, Jain N. Disease course in patients with pentosan polysulfate sodium–associated maculopathy after drug cessation. JAMA Ophthalmol. Published online July 9, 2020. doi:10.1001/ jamaophthalmol.2020.2349 Pentosan polysulfate sodium (PPS) is the only FDA approved medication for the treatment of
- [Primary Retinal Detachment Outcomes Study Report Number 2: Phakic Retinal Detachment Outcomes](https://vitbucklesociety.org/2020/09/01/primary-retinal-detachment-outcomes-study-report-number-2-phakic-retinal-detachment-outcomes/) - Written by: Brian C. Toy, MD September 2020 EH Ryan, CM Ryan, NJ Forbes, et al. Primary Retinal Detachment Outcomes Study Report Number 2: Phakic Retinal Detachment Outcomes. Ophthalmology. 2020 Aug;127(8):1077-1085. doi: 10.1016/j.ophtha.2020.03.007. Epub 2020 Mar 9. The Primary Retinal Detachment Outcomes (PRO) Study assessed anatomic and visual outcomes among contemporary RRD cases performed employing SB, PPV,
- [Management of Infantile and Childhood Retinopathies: Optimized Pediatric Pars Plana Vitrectomy Sclerotomy Nomogram](https://vitbucklesociety.org/2020/09/10/management-of-infantile-and-childhood-retinopathies-optimized-pediatric-pars-plana-vitrectomy-sclerotomy-nomogram/) - Written by: Edward H. Wood, MD September 2020 Wright LM, Harper A, Chang EY. Management of Infantile and Childhood Retinopathies: Optimized Pediatric Pars Plana Vitrectomy Sclerotomy Nomogram. Ophthalmol Retina. 2018 Dec;2(12):1227-1234. doi: 10.1016/j.oret.2018.06.008. Epub 2018 Aug 16. This excellent paper provides important surgical data for retina specialists taking care of pediatric patients. A relatively larger
- [Timing of Peak Vision Gains in Patients with Neovascular Age-related Macular Degeneration Treated with Ranibizumab](https://vitbucklesociety.org/2020/09/18/timing-of-peak-vision-gains-in-patients-with-neovascular-age-related-macular-degeneration-treated-with-ranibizumab/) - Written by: Mehnaz Khan, MD September 2020 Khurana RN, Chang L, Day BM, Ghanekar A, Stoilov I. Timing of Peak Vision Gains in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab. Ophthalmol Retina. 2020;4(8):760-766. doi:10.1016/j.oret.2020.02.011 It is widely accepted that the treatment of neovascular age-related macular degeneration (nAMD) includes intravitreal injections of anti-vascular endothelial growth
- [Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration](https://vitbucklesociety.org/2020/09/30/efficacy-of-every-four-monthly-and-quarterly-dosing-of-faricimab-vs-ranibizumab-in-neovascular-age-related-macular-degeneration/) - Written by: Maxwell S. Stem, MD September 2020 Khanani AM, Patel SS, Ferrone PJ, Osborne A, Sahni J, Grzeschik S, Basu K, Ehrlich JS, Haskova Z, Dugel PU. Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration (The STAIRWAY Phase 2 Randomized Clinical Trial). JAMA Ophthalmol. 2020;138(9):964-972.
- [Vitrectomy as an Aerosol-Generating Procedure in the Time of COVID-19: The VAPOR Study](https://vitbucklesociety.org/2020/10/10/vitrectomy-as-an-aerosol-generating-procedure-in-the-time-of-covid-19-the-vapor-study/) - Written by: Prethy Rao, MD MPH October 2020 Okada M, Cordeiro Sousa D, Fabinyi DCA, Hadoux X, Edwards TL, Brown KD, Chiu D, Dawkins RCH, Allen PJ, Yeoh J, Van Wijngaarden. Ophthalmology Retina. Article in Press. In the era of COVID-19 and concerns of transmission during ophthalmic surgery, retina specialists are faced with continued concerns
- [C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial](https://vitbucklesociety.org/2020/10/21/c5-inhibitor-avacincaptad-pegol-for-geographic-atrophy-due-to-age-related-macular-degeneration-a-randomized-pivotal-phase-2-3-trial/) - Written by: Katherine E. Talcott, MD October 2020 Jaffe GJ, Westby K, Csaky KG, Monés J, Pearlman JA, Patel SS, Joondeph BC, Randolph J, Masonson H, Rezaei KA, C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial, Ophthalmology (2020), doi: https://doi.org/10.1016/j.ophtha.2020.08.027. While there are multiple treatment
- [Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial](https://vitbucklesociety.org/2020/11/02/comparison-of-ranibizumab-with-or-without-verteporfin-photodynamic-therapy-for-polypoidal-choroidal-vasculopathy-the-everest-ii-randomized-clinical-trial/) - November 2020 Lim TH, Lai TYY, Takahashi K et al. Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial. JAMA Ophthalmol. Sept 2020; 138(9): 935-942. Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular age-related macular degeneration characterized by aneurysmal polypoidal lesions best imaged with
- [Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice](https://vitbucklesociety.org/2020/11/10/risk-of-systemic-adverse-events-after-intravitreal-bevacizumab-ranibizumab-and-aflibercept-in-routine-clinical-practice-2/) - Written by: Joshua D. Levinson, MD November 2020 Maloney MH, Payne SR, Herrin J, et al. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice. Ophthalmol. Published online August 2020. doi:10.1016/j.ophtha.2020.07.062 Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have become the standard of care in the treatment of multiple
- [Paracentral and Cecocentral Scotomas after Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment](https://vitbucklesociety.org/2020/11/16/paracentral-and-cecocentral-scotomas-after-pars-plana-vitrectomy-for-rhegmatogenous-retinal-detachment/) - Written by: Vlad Matei, MD November 2020 Khurana RN, Patel VR. Paracentral and cecocentral scotomas after pars plana vitrectomy for rhegmatogenous retinal detachment. Am J Ophthalmol 2020;219:163-169. Pars plana vitrectomy (PPV) is the most commonly employed procedure in the repair of rhegmatogenous retinal detachment (RRD). While preoperative factors, especially the degree of macular detachment, most
- [Randomized Safety and Feasibility Trial of Ultra-Rapid Cooling Anesthesia for Intravitreal Injections](https://vitbucklesociety.org/2020/11/30/randomized-safety-and-feasibility-trial-of-ultra-rapid-cooling-anesthesia-for-intravitreal-injections/) - Written by: Akshay S. Thomas, MD November 2020 Besirli CG, Smith SJ, Zacks DN, Gardner TW, Pipe KP, Musch DC, Shah AR. Randomized Safety and Feasibility Trial of Ultra-Rapid Cooling Anesthesia for Intravitreal Injections. Ophthalmol Retina. 2020 Oct;4(10):979-986. doi: 10.1016/j.oret.2020.04.001. Epub 2020 Apr 15. PMID: 32446842; PMCID: PMC7541410. Intravitreal injection is by far the most
- [Intraocular Pressure Changes and Vascular Endothelial Growth Factor Inhibitor Use in Various Retinal Diseases: Long-Term Outcomes in Routine Clinical Practice: Data from the Fight Retinal Blindness! Registry](https://vitbucklesociety.org/2020/12/01/intraocular-pressure-changes-and-vascular-endothelial-growth-factor-inhibitor-use-in-various-retinal-diseases-long-term-outcomes-in-routine-clinical-practice-data-from-the-fight-retinal-blindness-r/) - Written by: Rehan M. Hussain, MD December 2020 Gabrielle PH, Nguyen V, Wolff B, et al. Intraocular Pressure Changes and Vascular Endothelial Growth Factor Inhibitor Use in Various Retinal Diseases: Long-Term Outcomes in Routine Clinical Practice: Data from the Fight Retinal Blindness! Registry. Ophthalmol Retina 2020 Sep;4(9):861-870. doi: 10.1016/j.oret.2020.06.020. Epub 2020 Jun 20. It is well
- [Retinal Specialist versus Artificial Intelligence Detection of Retinal Fluid from OCT](https://vitbucklesociety.org/2020/12/19/retinal-specialist-versus-artificial-intelligence-detection-of-retinal-fluid-from-oct/) - Written by: Mohsin H. Ali, MD December 2020 Keenan TDL, Clemons TE, Domalpally A, Elman MJ, Havilio M, Agrón E, Benyamini G, Chew EY. Retinal Specialist versus Artificial Intelligence Detection of Retinal Fluid from OCT: Age-Related Eye Disease Study 2: 10-Year Follow-On Study. Ophthalmology. 2020 Jun 27:S0161-6420(20)30580-7. doi: 10.1016/j.ophtha.2020.06.038. Epub ahead of print. PMID: 32598950.
- [Aqueous Chlorhexidine Compared to Povidone Iodine as Ocular Antisepsis Prior to Intravitreal Injection: A Randomized Clinical Trial](https://vitbucklesociety.org/2020/12/30/aqueous-chlorhexidine-compared-to-povidone-iodine-as-ocular-antisepsis-prior-to-intravitreal-injection-a-randomized-clinical-trial/) - Written by: Daniel Su, MD December 2020 Ali FS, Jenkins TL, Boparai RS, Obeid A, Ryan ME, Wibblesman TD, Chiang A, Garg SJ; Post-Injection Endophthalmitis (PIE) Study Group. Aqueous Chlorhexidine Compared to Povidone Iodine as Ocular Antisepsis Prior to Intravitreal Injection: A Randomized Clinical Trial. Ophthalmol Retina. 2020 Nov 19:S2468-6530(20)30458-9 Topical providone iodine (PI) is
- [Frequency of Rhegmatogenous Retinal Detachment after Intravitreal Therapy in Neovascular Age-Related Macular Degeneration](https://vitbucklesociety.org/2021/01/07/frequency-of-rhegmatogenous-retinal-detachment-after-intravitreal-therapy-in-neovascular-age-related-macular-degeneration/) - Written by: Priya Sharma Vakharia, MD Jan 2021 Mammo DA, Ringeisen AL, Parke DW. Frequency of rhegmatogenous retinal detachment after intravitreal therapy in neovascular age-related macular degeneration. Ophthalmology Retina 2020; 4:973-8. The purpose of this study was to look at patients who developed rhegmatogenous retinal detachment (RRD) within 90 days of intravitreal injection for neovascular
- [Factors Associated With the Use of 360-Degree Laser Retinopexy During Primary Vitrectomy With or Without Scleral Buckle for Rhegmatogenous Retinal Detachment and Impact on Surgical Outcomes](https://vitbucklesociety.org/2021/01/16/factors-associated-with-the-use-of-360-degree-laser-retinopexy-during-primary-vitrectomy-with-or-without-scleral-buckle-for-rhegmatogenous-retinal-detachment-and-impact-on-surgical-outcomes/) - Written by: Andrew Tye, MD January 2021 Wang JC, Ryan EH, Ryan C, Kakulavarapu S, Mardis PJ, Rodriguez M, Stefater JA, Forbes NJ, Gupta O, Capone A Jr, Emerson GG, Joseph DP, Eliott D, Yonekawa Y; Primary Retinal Detachment Outcomes (PRO) Study Group. FACTORS ASSOCIATED WITH THE USE OF 360-DEGREE LASER RETINOPEXY DURING PRIMARY VITRECTOMY
- [Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study](https://vitbucklesociety.org/2021/01/24/macular-atrophy-incidence-and-progression-in-eyes-with-neovascular-age-related-macular-degeneration-treated-with-vascular-endothelial-growth-factor-inhibitors-using-a-treat-and-extend-or-a-pro-re-nata/) - Written by: Wenlan (Wendy) Zhang, MD January 2021 Spooner KL, Fraser-Bell S, Cozzi M, Staurenghi G, Invernizzi A, Monteduro D, Munk MR, Hong T, Chang AA. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of
- [Endophthalmitis after Cataract Surgery: Changes in Management Based on Microbiologic Cultures](https://vitbucklesociety.org/2021/02/01/endophthalmitis-after-cataract-surgery-changes-in-management-based-on-microbiologic-cultures/) - Written by: Philip P. Storey, MD Feb 2021 Samir N. Patel, MD, Philip P. Storey, MD, MPH, Hannah Levin, BS, Maitri Pancholy, MD, Anthony Obeid, MD, MPH, Turner D. Wibbelsman, BS, Brandon Kuley, BA, Allen C. Ho, MD, Jason Hsu, MD, Sunir J. Garg, MD, James F. Vander, MD, James P. Dunn, MD. Ophthalmology Retina
- [Outcomes of Combined Phacoemulsification and Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment: A Comparative Study](https://vitbucklesociety.org/2021/02/11/outcomes-of-combined-phacoemulsification-and-pars-plana-vitrectomy-for-rhegmatogenous-retinal-detachment-a-comparative-study/) - Written by: Jaya B. Kumar, MD February 2021 Tan A, Bertrand-Boiché M, Angioi-Duprez K, Berrod J, Conart J. Outcomes of Combined Phacoemulsification and Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment: A Comparative Study. Retina 2021; 41:68-74. For the majority of retina surgeons, pars plana vitrectomy (PPV) has become the preferred technique to repair primary rhegmatogenous
- [Eplerenone for Chronic Central Serous Chorioretinopathy - (VICI): a Randomised, Double-blind, Placebo-Controlled Trial](https://vitbucklesociety.org/2021/02/23/eplerenone-for-chronic-central-serous-chorioretinopathy-vici-a-randomised-double-blind-placebo-controlled-trial/) - Written by: Christian J. Sanfilippo, MD February 2021 Lotery, A., Sivaprasad, S., O’Connell, A., Harris, R. A., Culliford, L., Ellis, L., … Chakravarthy, U. (2020). Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. The Lancet, 395(10220), 294–303. doi:10.1016/s0140-6736(19)32981-2 Central serous chorioretinopathy
- [Cost Analysis of Routine Vitrectomy Surgery](https://vitbucklesociety.org/2021/03/04/cost-analysis-of-routine-vitrectomy-surgery/) - Written by: Avni P. Finn, MD March 2021 Berkowitz S.T., Sternberg P., Jr & Patel S., Cost Analysis of Routine Vitrectomy Surgery, Ophthalmology Retina, Published February 11, 2021, DOI: https://doi.org/10.1016/j.oret.2021.02.003. Due to rising healthcare costs, value-based healthcare reform has been at the forefront of healthcare delivery and policy. In this model, healthcare is reimbursed according
- [Progression of Geographic Atrophy with Subsequent Exudative Neovascular Disease in Age-Related Macular Degeneration](https://vitbucklesociety.org/2021/03/15/progression-of-geographic-atrophy-with-subsequent-exudative-neovascular-disease-in-age-related-macular-degeneration/) - Written by: Mehnaz Khan, MD March 2021 Hwang CK, Agrón E, Domalpally A, Cukras CA, Wong WT, Chew EY, Keenan TDL; AREDS2 Research Group. Progression of Geographic Atrophy with Subsequent Exudative Neovascular Disease in Age-Related Macular Degeneration: AREDS2 Report 24. Ophthalmol Retina. 2021 Feb;5(2):108-117. doi: 10.1016/j.oret.2020.10.008. Epub 2020 Oct 16. PMID: 33075546; PMCID: PMC7870515. One
- [Patterns and Predictors of Successful Treatment Discontinuation in Retinal Vein Occlusions with Macular Edema in the Real World](https://vitbucklesociety.org/2021/03/28/patterns-and-predictors-of-successful-treatment-discontinuation-in-retinal-vein-occlusions-with-macular-edema-in-the-real-world/) - Written by: Nika Bagheri, MD March 2021 Therlinder Lo, Lent-Schochet D, Luu KY, Kuriyan AE, Weiss MY, Rachitskaya AV, Singh RP, Wai KM, Campbell JP, Gupta K, Nudleman E, Chen KC, Yiu G. Patterns and Predictors of Successful Treatment Discontinuation in Retinal Vein Occlusions with Macular Edema in the Real World. OSLI Retina 2021; 52(2):84-92.
- [Clinical Presentation of Rhegmatogenous Retinal Detachment during the COVID-19 Pandemic: A Historical Cohort Study](https://vitbucklesociety.org/2021/04/07/clinical-presentation-of-rhegmatogenous-retinal-detachment-during-the-covid-19-pandemic-a-historical-cohort-study/) - Written by: Durga S. Borkar, MD April 2021 Patel LG, Peck T, Starr MR, Ammar MJ, Khan MA, Yonekawa Y, Klufas MA, Regillo CD, Ho AC, Xu D. Clinical Presentation of Rhegmatogenous Retinal Detachment during the COVID-19 Pandemic: A Historical Cohort Study. Ophthalmology (2020). doi: 10.1016/j.ophtha.2020.10.009 At present, it has been over one year since
- [Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes: A Randomized Clinical Trial](https://vitbucklesociety.org/2021/06/10/intravitreal-aflibercept-injection-vs-sham-as-prophylaxis-against-conversion-to-exudative-age-related-macular-degeneration-in-high-risk-eyes-a-randomized-clinical-trial/) - Written by: Brian K. Do, MD June 2021 Heier JS, Brown DM, Shah SP, Saroj N, Dang S, Waheed NK, Wykoff CC, Prenner JL, Boyer DS. Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes: A Randomized Clinical Trial. JAMA Ophthalmol. 2021 Mar 18:e210221. doi: 10.1001/jamaophthalmol.2021.0221. Epub
- [Comparison of 25- and 27-gauge Sutureless Cannula-Based Intraocular Lens Scleral Fixation Visual Acuity Outcomes and Complication Rates](https://vitbucklesociety.org/2021/06/25/comparison-of-25-and-27-gauge-sutureless-cannula-based-intraocular-lens-scleral-fixation-visual-acuity-outcomes-and-complication-rates/) - Written by: Maxwell S. Stem, MD June 2021 Kadakia AB, Wong TP, Wykoff CC, Shar AR. Comparison of 25- and 27-gauge Sutureless Cannula-Based Intraocular Lens Scleral Fixation Visual Acuity Outcomes and Complication Rates. Retina. 2021;41(5):940-946. When an intraocular lens (IOL) cannot be safely placed “in the bag,” options for IOL placement include the anterior chamber,
- [Clinical Outcomes and Treatment Course of Eyes with Neovascular Age-Related Macular Degeneration Following the Development of Endophthalmitis](https://vitbucklesociety.org/2021/07/10/clinical-outcomes-and-treatment-course-of-eyes-with-neovascular-age-related-macular-degeneration-following-the-development-of-endophthalmitis/) - Written by: Judy Chen, MD July 2021 Koulisis N, Moysidis S, Govindaraju V, et al. Clinical Outcomes and Treatment Course of Eyes with Neovascular Age-Related Macular Degeneration Following the Development of Endophthalmitis. Retina 2021; 41(6):1242-1250. Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) medication are the current gold standard of care for patients with neovascular
- [Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice](https://vitbucklesociety.org/2021/07/26/risk-of-systemic-adverse-events-after-intravitreal-bevacizumab-ranibizumab-and-aflibercept-in-routine-clinical-practice-3/) - Written by: Christopher Aderman, MD July 2021 Maloney MH, Payne SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice. Ophthalmology. 2021 Mar;128(3):417-424. doi: 10.1016/j.ophtha.2020.07.062. Epub 2020 Aug 8. PMID: 32781110. An unfortunate problem we encounter not infrequently in clinic is
- [Pneumatic Vitreolysis with C3F8 for Vitreomacular Traction with and without Macular Hole: DRCR Retina Network Protocols AG and AH](https://vitbucklesociety.org/2021/08/08/pneumatic-vitreolysis-with-c3f8-for-vitreomacular-traction-with-and-without-macular-hole-drcr-retina-network-protocols-ag-and-ah-2/) - Written by: Joshua D. Levinson, MD August 2021 Chan CK, Mein CE, Glassman AR, et al. Pneumatic Vitreolysis with C3F8 for Vitreomacular Traction with and without Macular Hole: DRCR Retina Network Protocols AG and AH. Ophthalmol. 2021 Treatment options for symptomatic vitreomacular traction (VMT) and macular hole (MH) include observation, pars plana vitrectomy and vitreolysis.
- [Long-term anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: the LATAR study. Report 1: ten-year, real-world outcomes.](https://vitbucklesociety.org/2021/08/24/long-term-anti-vascular-endothelial-growth-factor-treatment-for-neovascular-age-related-macular-degeneration-the-latar-study-report-1-ten-year-real-world-outcomes-2/) - Written by: Vlad Matei, MD August 2021 Spooner K, Fraser-Bell S, Hong T, et al. Long-term anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: the LATAR study. Report 1: ten-year, real-world outcomes. Ophthalmology Retina 2021;5(6):511-518. Neovascular age-related macular degeneration (nAMD) is one of the most common and debilitating diseases encountered by retinal specialists.
- [Two-year results of the phase 3 randomized controlled study of abicipar in neovascular age-related macular degeneration](https://vitbucklesociety.org/2021/08/30/two-year-results-of-the-phase-3-randomized-controlled-study-of-abicipar-in-neovascular-age-related-macular-degeneration-2/) - Written by: Akshay S. Thomas, MD August 2021 Khurana RN, Kunimoto D, Yoon YH, et al. Two-year results of the phase 3 randomized controlled study of abicipar in neovascular age-related macular degeneration. Ophthalmology. 2021;128(7):1027-1038. Treatment options for wet AMD in 2019 included off-label use of bevacizumab or use of an FDA-approved agent, ranibizumab or
- [Machine Learning Can Predict Anti–VEGF Treatment Demand in a Treat-and-Extend Regimen for Patients with Neovascular AMD, DME, and RVO Associated Macular Edema](https://vitbucklesociety.org/2021/09/06/machine-learning-can-predict-anti-vegf-treatment-demand-in-a-treat-and-extend-regimen-for-patients-with-neovascular-amd-dme-and-rvo-associated-macular-edema-2/) - Written by: Mohsin H. Ali, MD September 2021 Gallardo, Mathias, et al. “Machine Learning Can Predict Anti–VEGF Treatment Demand in a Treat-and-Extend Regimen for Patients with Neovascular AMD, DME, and RVO Associated Macular Edema.” Ophthalmology Retina, vol. 5, no. 7, 2021, pp. 604–624., doi:10.1016/j.oret.2021.05.002. Machine learning artificial intelligence models have the potential to improve our
- [Microcystic Macular Edema and Cystoid Macular Edema Before and After Epiretinal Membrane Surgery](https://vitbucklesociety.org/2021/09/20/microcystic-macular-edema-and-cystoid-macular-edema-before-and-after-epiretinal-membrane-surgery/) - Written by: Edward H. Wood, MD September 2021 Lee Dong Hyun, Sung Eun Park, and Christopher Seungkyu Lee. 2020. “Microcystic Macular Edema and Cystoid Macular Edema Before and After Epiretinal Membrane Surgery.” Retina Publish Ahead of Print (December). https://doi.org/10.1097/IAE.0000000000003087. This study is clinically useful by expanding our understanding of imaging biomarkers of idiopathic epiretinal membranes (ERM)
- [Epiretinal Membrane Surgery after Retinal Detachment Repair: Visual Acuity Outcomes and OCT Analysis](https://vitbucklesociety.org/2021/10/07/epiretinal-membrane-surgery-after-retinal-detachment-repair-visual-acuity-outcomes-and-oct-analysis/) - Written by: Daniel Su, MD October 2021 Soares RR, Mahmoudzadeh R, Salabati M, Massenzio E, Israilevich R, Patel SN, Hinkle J, Kuriyan AE, Hsu J, Garg SJ, Khan MA. Epiretinal Membrane Surgery after Retinal Detachment Repair: Visual Acuity Outcomes and OCT Analysis. Ophthalmol Retina. 2021 Mar 29:S2468-6530(21)00103-2. Epiretinal membrane (ERM) formation commonly occurs after primary
- [End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration](https://vitbucklesociety.org/2021/10/07/end-of-study-results-for-the-ladder-phase-2-trial-of-the-port-delivery-system-with-ranibizumab-for-neovascular-age-related-macular-degeneration-2/) - Written by: Philip P. Storey, MD October 2021 Khanani A, Callanan D, Dreyer R, Chen S, Howard J, Hopkins J, Lin C, Lorenz-Candlin M, Makadia S, Patel S, Tam T, Gune S. End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology Retina 2021;5:775-787.
- [Development of Macular Atrophy after Pars Plana Vitrectomy for Myopic Traction Maculopathy and Macular Hole Retinal Detachment in Pathologic Myopia](https://vitbucklesociety.org/2021/10/19/development-of-macular-atrophy-after-pars-plana-vitrectomy-for-myopic-traction-maculopathy-and-macular-hole-retinal-detachment-in-pathologic-myopia-2/) - Written by: Musa Abdelaziz, MD October 2021 Fang, Y et al. “Development of macular atrophy after pars plana vitrectomy for myopic traction maculopathy and macular hole retinal detachment in pathologic myopia.” Retina. 2020 Oct;40(10):1881-1893. DOI: 10.1097/IAE.0000000000002709. Pathologic myopia (PM) is a major cause of legal blindness worldwide. The most serious lesion associated with severe vision
- [Risk Factors for Severe Bleeding Complications in Vitreoretinal Surgery and the Role of Antiplatelet or Anticoagulant Agents](https://vitbucklesociety.org/2021/10/31/risk-factors-for-severe-bleeding-complications-in-vitreoretinal-surgery-and-the-role-of-antiplatelet-or-anticoagulant-agents-2/) - Written by: Wenlan (Wendy) Zhang, MD October 2021 Lauermann P, Klingelhöfer A, Mielke D, van Oterendorp C, Hoerauf H, Striebe NA, Storch MW, Pfeiffer S, Koscielny J, Sucker C, Bemme S, Feltgen N. Risk Factors for Severe Bleeding Complications in Vitreoretinal Surgery and the Role of Antiplatelet or Anticoagulant Agents. Ophthalmol Retina. 2021 Aug;5(8):e23-e29. Many
- [Persistent Opioid Use After Ophthalmic Surgery in Opioid-Naïve Patients and Associated Risk Factors](https://vitbucklesociety.org/2022/01/03/persistent-opioid-use-after-ophthalmic-surgery-in-opioid-naive-patients-and-associated-risk-factors/) - Written by: Priya Sharma Vakharia, MDRetina Vitreous Associates of FloridaPalm Harbor & St. Petersburg, FL January 2022 Ung C, Yonekawa Y, Waljee J, et al. Persistent opioid use after ophthalmic surgery in opioid-naïve patients and associated factors. Ophthalmology 2021; 128(9): 1266-1273. This is a retrospective claims-based cohort analysis, using a database (Optum ClinformaticsÒ DataMart Database)

## Pages

- [Home](https://vitbucklesociety.org/) - Welcome to the Vit-Buckle Society, a professional non-profit organization for vitreoretinal surgeons and students.
- [Meetings](https://vitbucklesociety.org/vbs-meetings/) - 2027 Annual Meeting 15th Annual Vit-Buckle Society MeetingApril 1-3, 2027 | Miami, FLAbstract Submission Deadline: October 26, 2026 at 11:59 PM PDT Next year’s Annual Meeting will be here before you know it! Abstract Submissions are open: Scientific Study on Surgical Topic (standard abstract required – Title, Objective, Methods, Results, Conclusion, 350 word maximum) My Craziest
- [FOCUS (nonfinal)](https://vitbucklesociety.org/focus-nonfinal/) - FOstering Careers for Upcoming Stars (FOCUS) for 2026 The Vit-Buckle Society is committed to supporting access to care in the field of surgical retina. As such, VBS is excited to bring back the highly popular FOstering Careers for Upcoming Stars (FOCUS) Program to increase the pipeline of people focused on patients who are underserved in
- [Early Career Retina Research Grant Program](https://vitbucklesociety.org/retina-research-grant/) - Call for Grant Submissions The Vit-Buckle Society invites applications for its inaugural Retina Surgery Research Grant Program. This program is designed to support innovative research that advances the science and practice of vitreoretinal surgery and improves outcomes for patients with retinal disease. The grant program seeks to foster the development of new surgical techniques, technologies,
- [FOstering Careers for Upcoming Stars (FOCUS)](https://vitbucklesociety.org/focus-program/) - Updates on the FOstering Careers for Upcoming Stars (FOCUS) program is forthcoming. Please check back later.
- [Academic Events](https://vitbucklesociety.org/academic-calendar/) - VBS Academic Calendar Upcoming Events in 2026 Educational events are hosted by the Vit-Buckle Society on a regular basis throughout the academic year. 8/11/26 - Surgical Rounds August 11th, 20268:30pm EST Registration: Zoom Webinar Join us for the next VBS Surgical Rounds, moderated by the Surgical Rounds team, Drs. Royce Chen, Vlad Diaconita, Grant Justin, John Miller,
- [Membership](https://vitbucklesociety.org/membership/) - Sign up to be a member of Vit-Buckle Society.
- [Women's International Travel Grant](https://vitbucklesociety.org/womens-international-travel-grant/) - Grant Application The deadline for submission has passed for the 2027 meeting.
- [Home (Test)](https://vitbucklesociety.org/home-test/) - President, Vit-Buckle Society Mrinali Gupta MDPresident-Elect, Vit-Buckle Society Aleksandra Rachitskaya, MDImmediate Past President, Vit-Buckle Society VBS Annual Meeting The VBS Annual Meeting has become one of the year’s most anticipated, engaging, and exciting conferences. Previous attendees describe their experience as, “I feel educated, inspired, and connected,” and “I am so grateful to the VBS family.
- [About](https://vitbucklesociety.org/about/) - Learn more about the Vit-Buckle society.
- [Account](https://vitbucklesociety.org/account/) - Log in to your Vit-Buckle Society member account.
- [2024 VBS Membership Renewal](https://vitbucklesociety.org/member-content/2024-vbs-membership-renewal/) - The Vit-Buckle Society is pleased to announce a transition to a calendar year membership structure. Commencing January 1, 2024, all memberships will align with the calendar year, necessitating renewal at the conclusion of the year. To facilitate a smooth transition, memberships that were renewed post-June 1, 2023 were automatically extended to accommodate the new cycle.
- [Media Library](https://vitbucklesociety.org/media-library/) - Browse the Vit-Buckle Society media library to view recent videos and publications from Vit-Buckle Society.
- [Fellow's Foray 2022](https://vitbucklesociety.org/fellows-foray-2022/) - We are excited for the Vit-­Buckle Society (VBS) Annual Meeting happening in Las Vegas at the Bellagio, April 13 – 15, 2023! In conjunction with the annual meeting, Evolve Medical Education will once again be hosting the very unique VBS Fellows’ Foray CME Event. As part of this event, we will be awarding 20 travel grants to US and international vitreoretinal fellows
- [Cookie Policy (EU)](https://vitbucklesociety.org/cookie-policy-eu/) - Review how our site collects and uses data from cookies.
- [Meetings and Events](https://vitbucklesociety.org/meetings-events/) - View details of upcoming events attended or hosted by Vit-Buckle Society.
- [VB Academy](https://vitbucklesociety.org/vb-academy/) - Through the Vit-Buckle Academy, we offer valuable free courses to help members grow their vitrectomy education.
- [VBS School of Finance - January 2022](https://vitbucklesociety.org/trainee-member-content/vbs-school-of-finance-january-2022/) - VBS School of Finance - January 2022 Hosted by: Niki Kothari, MD; Andrew Schimel, MD; Geeta Lalwani, MD On Tuesday, January 25th, VBS hosted the virtual VBS School of Finance. We have spent years becoming successful vitreoretinal surgeons, yet most of us have little financial education. Join us to get your money questions answered and
- [Journal Club CME](https://vitbucklesociety.org/journal-club-cme/) - VBS Journal Club CME Thank you for reading the VBS Journal Club! We hope that the Journal Club articles have been helpful and have supported your education/practice. Participation in the Journal Club is eligible for AMA PRA Category 1 Credit(s)™. Most articles are eligible for CME and can be found via the EvolveMedEd VBS Portal;
- [Industry Sponsorships and Donations](https://vitbucklesociety.org/support-vbs/) - Become a Vit-Buckle Society sponsor or donor.
- [Login](https://vitbucklesociety.org/login/) - Login to your Vit-Buckle Society account.
- [Contact Us](https://vitbucklesociety.org/contact-us/) - Get in touch with Vit-Buckle Society Leadership.
- [Terms of Use](https://vitbucklesociety.org/terms-of-use/) - Review the Vit-Buckle Society's site and member terms of use.
- [Member Content](https://vitbucklesociety.org/member-content/) - Access Vit-Buckle Society members-only content.
- [Privacy Policy](https://vitbucklesociety.org/privacy-policy/) - Review the Vit-Buckle Society's site privacy policy to learn what data we collect and how we collect it.
- [Thank You](https://vitbucklesociety.org/thank-you/) - Thank you for submitting your subscription details.
- [Trainee Member Content](https://vitbucklesociety.org/trainee-member-content/) - Access the Vit-Buckle Society's members-only trainee content.
- [Accessibility Statement](https://vitbucklesociety.org/accessibility-statement/) - Review the accessibility standards our website adheres to.
- [Sample Trainee Member 1](https://vitbucklesociety.org/trainee-member-content/sample-trainee-member-1/) - Sample trainee member 1 content
- [Sample Member 1](https://vitbucklesociety.org/member-content/sample-member-1/) - Sample member 1 content

## Memberships

- [2027 VBS Membership](https://vitbucklesociety.org/register/2027-vbs-membership/) - We encourage you to renew your VBS Membership for 2027. Please use the below form to renew your existing VBS membership for 2027. Membership is charged on a calendar-year basis. As a reminder, you must have an active membership to attend the Annual Meeting. If you are not a member of VBS or your trainee
- [Honorary Member](https://vitbucklesociety.org/register/honorary-member/)
- [Trainee Member](https://vitbucklesociety.org/register/pgmn-trainee-member/) - Join the Vit-Buckle Society. Trainee membership connects you with passionate vitreoretinal specialists from the national and international community who are dedicated to teaching, research and serving our patients.
- [2026 VBS Membership](https://vitbucklesociety.org/register/2026-vbs-membership/) - We encourage you to renew your VBS Membership for 2026. Please use the below form to renew your existing VBS membership for 2026. Membership is charged on a calendar-year basis. As a reminder, you must have an active membership to attend the Annual Meeting. If you are not a member of VBS or your trainee
- [2025 VBS Membership](https://vitbucklesociety.org/register/2025-vbs-membership/)
- [2024 VBS Membership - Expired](https://vitbucklesociety.org/register/2024-vbs-membership/)
- [Member](https://vitbucklesociety.org/register/member/)

## Meetings

- [Annual Meeting 2026](https://vitbucklesociety.org/meetings/annual-meeting-2026/) - 14th Annual Vit-Buckle Society MeetingApril 9-11, 2026 | Fontainebleau in Las Vegas, NV The goal of the Vit-Buckle Society annual meeting is to create an intimate, interactive, discussion-oriented atmosphere aimed at nurturing innovative surgical and medical therapeutic approaches and technologies in order to foster best practices for the management of retinal pathologies. VIEW AGENDA AND CME
- [Annual Meeting 2025](https://vitbucklesociety.org/meetings/annual-meeting-2025/) - 13th Annual Vit-Buckle Society Annual Meeting The 13th VBS Annual Meeting concluded March 20-22, 2025 in Austin, TX. Honored physicians included Dr. Emily Chew (recipient of the Lifetime Achievement Award) and Dr. Audina Berrocal (Mentorship Award) along with Surgical/Medical sessions, Lightning rounds, Debates and the Fellows and FOCUS Programs. The meeting featured a Wild Wild West
- [Annual Meeting 2022](https://vitbucklesociety.org/meetings/vbs-2022/) - The 10th VBS Annual Meeting concluded March 2022 in Las Vegas. We thank you for your attendance and support!
- [Annual Meeting 2024](https://vitbucklesociety.org/meetings/annual-meeting-2024/) - 12th Annual Vit-Buckle Society Annual Meeting Fontainebleau in Miami Beach, FL April 4-6, 2024 The 12th Annual Vit-Buckle Society (VBS) Annual Meeting took place in April 2024 at the Fontainebleau in Miami Beach, FL. We are thankful for the support of our guest speakers, VBS members, FOCUS program participants, fellows/residents, and industry representatives that came
- [Annual Meeting 2023](https://vitbucklesociety.org/meetings/annual-meeting-2023/) - The 11th VBS Annual Meeting Bellagio Las VegasApril 13-15, 2023 We are thrilled to announce the date for the 11th Annual Vit-Buckle Society (VBS) Annual Meeting. Our annual meeting will take place at the Bellagio, in Las Vegas, NV from April 13-15, 2023! Please save the date! Our 2023 VBS Annual Meeting promises to

## Courses

- [Vitrectomy Basics](https://vitbucklesociety.org/courses/vitrectomy-basics/) - Before the Case Which Gauge? Depends on the pathology, surgeon preference, and instrumentation. Postoperative inflammation and comfort improve with smaller gauges, as do the opportunities for self-sealing wounds. Smaller gauge and the shorter distance from instrument tip to the port may enable cutter-enabled membrane segmentation and delamination. However, some instrumentation may not be available in

## Videos

- [PRO STUDY GROUP PAPERS: PART 2](https://vitbucklesociety.org/videos/pro-study-group-papers-part-2/) - Jayanth Sridhar, MD; Brian K. Do, MD; Sabin Dang, MD; Avni P. Finn, MD, MBA
- [PRO STUDY GROUP PAPERS: PART 1](https://vitbucklesociety.org/videos/pro-study-group-papers-part-1/) - Jayanth Sridhar, MD; Brian K. Do, MD; and Avni Finn, MD, MBA
- [PROTOCOL W: HOW MIGHT THE DATA CHANGE PRACTICE?](https://vitbucklesociety.org/videos/protocol-w-how-might-the-data-change-practice/) - Yoshihiro Yonekawa, MD; Ajay Kuriyan, MD; Anton Orlin, MD; and Paula Pecen, MD
- [AUTOLOGOUS RETINA TRANSPLANT FOR MACULAR HOLES](https://vitbucklesociety.org/videos/autologous-retina-transplant-for-macular-holes/) - Caroline R. Baumal, MD; M. Ali Khan, MD; and Christina Y. Weng, MD, MBA
- [MASKING IN RETINA: KEEPING PATIENTS SAFE FROM BACTERIAL EXPOSURE](https://vitbucklesociety.org/videos/masking-in-retina-keeping-patients-safe-from-bacterial-exposure/) - Yoshihiro Yonekawa, MD; and Ajay E. Kuriyan, MD, MS

## Categories

- [Uncategorized](https://vitbucklesociety.org/category/uncategorized/)
- [Journal Club](https://vitbucklesociety.org/category/journal-club/)

## Video Categories

- [Las Vegas 2014](https://vitbucklesociety.org/video-category/las-vegas-2014/)